Skip to main content
Smart Investors Daily
PB

AMEX · PBD

Invesco Global Clean Energy ETF

Financial Services · Asset Management - Global

$13.65

Down-$0.70 (-5.13%)

Updated Nov 20, 2026, 8:01 PM

SID Score

3.4/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
84.57M
P/E ratio
—
Dividend yield
2.86%
52-week range
$13.65 – $22.58
Volume
35.1K
Avg. volume
107.63K

Price performance · PBD

PBD price history

1M range · 0 trading sessions · Daily adjusted prices

PBD does not have enough price history for the selected period.

Data unavailable

Market data is busy. Please try again shortly.

Latest PBD news

The latest Smart Investors Daily articles mentioning PBD.

PBD research

Overview

Company profile and research snapshot.

Company profile

The fund generally will invest at least 90% of its total assets in the securities that comprise the underlying index, as well as American depositary receipts ("ADRs") and global depositary receipts ("GDRs") that represent securities in the underlying index. The underlying index is comprised primarily of companies whose technologies focus on the generation and use of cleaner energy, conservation and efficiency, and the advancement of renewable energy in general, as determined by the index provider.

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Nov 3, 2026

Protalix BioTherapeutics to Announce Third Quarter 2026 Financial Results and Business Update on November 10, 2026

Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the discovery, development, production, and commercialization of innovative therapeutics for rare diseases with significant unmet needs, today announced that it will release its financial results for the quarter ended September 30, 2026 and provide a business update on November 10, 2026.

Yahoo · Oct 26, 2026

Protalix BioTherapeutics to Present at the Stifel 2026 Healthcare Conference

Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the discovery, development, production, and commercialization of innovative therapeutics for rare diseases with significant unmet needs, today announced that Dror Bashan, President and Chief Executive Officer, is scheduled to present at the Stifel 2026 Healthcare Conference. The Conference is being held on November 10-12, 2026 at the Lotte New York Palace Hotel, New York City, NY.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.